{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:55:56Z","timestamp":1792007756967,"version":"4.4.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Eisai Korea Inc. Seoul, Republic of Korea","award":["4-2024-0700"],"award-info":[{"award-number":["4-2024-0700"]}]},{"name":"Yuhan Corporation, Seoul, Republic of Korea","award":["4-2025-0044"],"award-info":[{"award-number":["4-2025-0044"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study aimed to develop a new scoring system for predicting recurrent thrombosis in patients with antiphospholipid syndrome (APS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective multicentre cohort study. Patients with APS were followed up from APS diagnosis to either recurrent thrombosis or their last follow-up date, whichever came first. A multivariable logistic regression analysis with a backward elimination was used to develop a new scoring system, incorporating conventional cardiovascular risk factors and antiphospholipid antibody (aPL) profile as covariates. Each covariate remaining in the final step was multiplied by its \u03b2 coefficient, rounded to the nearest integer, and then summed. A multivariable Cox proportional hazard model, adjusted for medication use, assessed the association between the new scoring system and recurrent thrombosis risk. The accuracy of the new scoring system in predicting recurrent thrombosis was evaluated by estimating the area under the curve (AUC) and comparing it with the adjusted global APS score (aGAPSS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 126 patients with APS were included. The median age of the cohort was 40 (interquartile range: 31\u201355) years and 49.2% were women. Hypertension, type 2 diabetes mellitus (T2DM), and dyslipidaemia were present in 20.6%, 18.3%, and 54.0% of the patients, respectively. 26.2% were current smokers and 23.8% had concomitant systemic lupus erythematosus. Lupus anticoagulant (LA), anti-\u03b22 glycoprotein I (anti-\u03b22GPI) IgG, anti-\u03b22GPI IgM, anti-cardiolipin (aCL) IgG, and aCL IgM were positive in 76.2%, 27.0%, 11.9%, 27.0%, and 6.3% of the patients, respectively. During a median follow-up duration of 41.5 (interquartile range: 21.4\u201372.0) months, thrombosis recurred in 9 (7.1%) patients. Multivariable logistic regression analysis revealed the following scoring system: modified diabetes global APS score (mdGAPSS)\u2009=\u20091*T2DM\u2009+\u20092*LA\u2009+\u20091*anti-\u03b22GPI. Multivariable Cox proportional hazard model showed that a higher score was significantly associated with an increased risk of recurrent thrombosis (adjusted hazard ratio 2.911, 95% confidence interval 1.090\u20137.770,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.033). The AUC was higher using the mdGAPSS (AUC\u2009=\u20090.706) than the aGAPSS (AUC\u2009=\u20090.553).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Compared to the aGAPSS, the mdGAPSS\u2014comprising T2DM, LA, and anti-\u03b22GPI\u2014demonstrated a greater accuracy in predicting recurrent thrombosis in patients with APS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42358-025-00476-1","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T18:30:22Z","timestamp":1758738622000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Development of a new scoring system for predicting recurrent thrombosis in patients with antiphospholipid syndrome"],"prefix":"10.1186","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7962-3697","authenticated-orcid":false,"given":"Oh Chan","family":"Kwon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3307-5215","authenticated-orcid":false,"given":"Jang Woo","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1189-7637","authenticated-orcid":false,"given":"Min-Chan","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4695-8620","authenticated-orcid":false,"given":"Yong-Beom","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8038-3341","authenticated-orcid":false,"given":"Sang-Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"key":"476_CR1","doi-asserted-by":"publisher","first-page":"1759720x2091085","DOI":"10.1177\/1759720X20910855","volume":"12","author":"M Rodziewicz","year":"2020","unstructured":"Rodziewicz M, D\u2019Cruz DP. An update on the management of antiphospholipid syndrome. Ther Adv Musculoskelet Dis. 2020;12:1759720x20910855.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"6","key":"476_CR2","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1136\/annrheumdis-2013-204838","volume":"74","author":"R Cervera","year":"2015","unstructured":"Cervera R, Serrano R, Pons-Estel GJ, Ceberio-Hualde L, Shoenfeld Y, de Ram\u00f3n E, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2015;74(6):1011\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"476_CR3","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1093\/rheumatology\/kes388","volume":"52","author":"S Sciascia","year":"2013","unstructured":"Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. GAPSS: the global Anti-Phospholipid syndrome score. Rheumatology (Oxford). 2013;52(8):1397\u2013403.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"476_CR4","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/rheumatology\/keu307","volume":"54","author":"S Sciascia","year":"2015","unstructured":"Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. The global anti-phospholipid syndrome score in primary APS. Rheumatology (Oxford). 2015;54(1):134\u20138.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"476_CR5","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1177\/0961203317703493","volume":"26","author":"N Fernandez Mosteirin","year":"2017","unstructured":"Fernandez Mosteirin N, Saez Comet L, Salvador Osuna C, Calvo Villas JM, Velilla Marco J. Independent validation of the adjusted GAPSS: role of thrombotic risk assessment in the real-life setting. Lupus. 2017;26(12):1328\u201332.","journal-title":"Lupus"},{"issue":"3","key":"476_CR6","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.semarthrit.2019.04.009","volume":"49","author":"M Radin","year":"2019","unstructured":"Radin M, Sciascia S, Erkan D, Pengo V, Tektonidou MG, Ugarte A, et al. The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: results from the APS ACTION cohort. Semin Arthritis Rheum. 2019;49(3):464\u20138.","journal-title":"Semin Arthritis Rheum"},{"issue":"15","key":"476_CR7","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1056\/NEJMoa1608664","volume":"376","author":"A Rawshani","year":"2017","unstructured":"Rawshani A, Rawshani A, Franz\u00e9n S, Eliasson B, Svensson AM, Miftaraj M, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017;376(15):1407\u201318.","journal-title":"N Engl J Med"},{"issue":"3","key":"476_CR8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S2213-8587(20)30431-9","volume":"9","author":"J Pearson-Stuttard","year":"2021","unstructured":"Pearson-Stuttard J, Bennett J, Cheng YJ, Vamos EP, Cross AJ, Ezzati M, et al. Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records. Lancet Diabetes Endocrinol. 2021;9(3):165\u201373.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"476_CR9","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1002\/acr.21701","volume":"64","author":"CE Rodrigues","year":"2012","unstructured":"Rodrigues CE, Bonf\u00e1 E, Caleiro MT, Vendramini MB, Bueno C, Lopes JB, et al. Association of arterial events with the coexistence of metabolic syndrome and primary antiphospholipid syndrome. Arthritis Care Res (Hoboken). 2012;64(10):1576\u201383.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"476_CR10","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.thromres.2015.10.029","volume":"136","author":"S Saraiva Sda","year":"2015","unstructured":"Saraiva Sda S, Cust\u00f3dio IF, Mazetto Bde M, Collela MP, de Paula EV, Appenzeller S, et al. Recurrent thrombosis in antiphospholipid syndrome May be associated with cardiovascular risk factors and inflammatory response. Thromb Res. 2015;136(6):1174\u20138.","journal-title":"Thromb Res"},{"issue":"2","key":"476_CR11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","volume":"4","author":"S Miyakis","year":"2006","unstructured":"Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295\u2013306.","journal-title":"J Thromb Haemost"},{"issue":"10","key":"476_CR12","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","volume":"78","author":"MG Tektonidou","year":"2019","unstructured":"Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296\u2013304.","journal-title":"Ann Rheum Dis"},{"key":"476_CR13","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-0431","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Malik S, Budoff MJ, Correa A, Ashley KE, Selvin E, et al. Identification and predictors for cardiovascular disease risk equivalents among adults with diabetes mellitus. Diabetes Care. 2021. https:\/\/doi.org\/10.2337\/dc21-0431.","journal-title":"Diabetes Care"},{"issue":"18","key":"476_CR14","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1161\/CIRCULATIONAHA.109.921072","volume":"121","author":"MS Dhamoon","year":"2010","unstructured":"Dhamoon MS, Elkind MS. Inclusion of stroke as an outcome and risk equivalent in risk scores for primary and secondary prevention of vascular disease. Circulation. 2010;121(18):2071\u20138.","journal-title":"Circulation"},{"issue":"5","key":"476_CR15","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1182\/blood-2002-02-0441","volume":"101","author":"M Galli","year":"2003","unstructured":"Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101(5):1827\u201332.","journal-title":"Blood"},{"issue":"6","key":"476_CR16","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.autrev.2013.11.004","volume":"13","author":"Q Reynaud","year":"2014","unstructured":"Reynaud Q, Lega JC, Mismetti P, Chapelle C, Wahl D, Cath\u00e9bras P, et al. Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev. 2014;13(6):595\u2013608.","journal-title":"Autoimmun Rev"},{"key":"476_CR17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ijcard.2017.02.155","volume":"240","author":"M Radin","year":"2017","unstructured":"Radin M, Schreiber K, Costanzo P, Cecchi I, Roccatello D, Baldovino S, et al. The adjusted global antiphospholipid syndrome score (aGAPSS) for risk stratification in young APS patients with acute myocardial infarction. Int J Cardiol. 2017;240:72\u20137.","journal-title":"Int J Cardiol"},{"issue":"4","key":"476_CR18","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1093\/rheumatology\/kex466","volume":"57","author":"S Sciascia","year":"2018","unstructured":"Sciascia S, Radin M, Sanna G, Cecchi I, Roccatello D, Bertolaccini ML. Clinical utility of the global anti-phospholipid syndrome score for risk stratification: a pooled analysis. Rheumatology (Oxford). 2018;57(4):661\u20135.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"476_CR19","first-page":"Cd012369","volume":"7","author":"CD Flumignan","year":"2022","unstructured":"Flumignan CD, Nakano LC, Baptista-Silva JC, Flumignan RL. Antiplatelet agents for the treatment of deep venous thrombosis. Cochrane Database Syst Rev. 2022;7(7):Cd012369.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"476_CR20","doi-asserted-by":"publisher","first-page":"346","DOI":"10.15386\/mpr-2519","volume":"96","author":"MA Moldovan","year":"2023","unstructured":"Moldovan MA, Filip LV, Ciurea M, Termure DA, Ostas D, Rotar H, et al. Bleeding and thromboembolic risk in patients under anticoagulant therapy receiving oral surgery: a systematic review. Med Pharm Rep. 2023;96(4):346\u201357.","journal-title":"Med Pharm Rep"},{"key":"476_CR21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/CLEP.S341048","volume":"14","author":"OA Ayodele","year":"2022","unstructured":"Ayodele OA, Cabral HJ, McManus DD, Jick SS. Glucocorticoids and risk of venous thromboembolism in asthma patients aged 20\u201359 years in the united kingdom\u2019s CPRD 1995\u20132015. Clin Epidemiol. 2022;14:83\u201393.","journal-title":"Clin Epidemiol"},{"issue":"11","key":"476_CR22","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1177\/09612033221114275","volume":"31","author":"CM Yelnik","year":"2022","unstructured":"Yelnik CM, Martin C, Ledoult E, Sanges S, Sobanski V, Farhat M, et al. Dyslipidemia is insufficiently treated in antiphospholipid syndrome patients. Lupus. 2022;31(11):1379\u201384.","journal-title":"Lupus"},{"issue":"4","key":"476_CR23","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1093\/rheumatology\/keab410","volume":"61","author":"OC Kwon","year":"2022","unstructured":"Kwon OC, Park YB, Park MC. Effect of statins on the prevention of recurrent thrombosis in thrombotic antiphospholipid syndrome. Rheumatology (Oxford). 2022;61(4):1548\u201355.","journal-title":"Rheumatology (Oxford)"},{"key":"476_CR24","doi-asserted-by":"crossref","unstructured":"Bucci T, Menichelli D, Palumbo IM, Pastori D, Ames PRJ, Lip GYH et al. Statins as an adjunctive antithrombotic agent in thrombotic antiphospholipid syndrome: mechanisms and clinical implications. Cells. 2025;14(5).","DOI":"10.3390\/cells14050353"},{"issue":"8","key":"476_CR25","doi-asserted-by":"publisher","first-page":"E301","DOI":"10.1503\/cmaj.091676","volume":"182","author":"M Chiu","year":"2010","unstructured":"Chiu M, Austin PC, Manuel DG, Tu JV. Comparison of cardiovascular risk profiles among ethnic groups using population health surveys between 1996 and 2007. CMAJ. 2010;182(8):E301\u201310.","journal-title":"CMAJ"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-025-00476-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42358-025-00476-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-025-00476-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:22:27Z","timestamp":1781608947000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s42358-025-00476-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["476"],"URL":"https:\/\/doi.org\/10.1186\/s42358-025-00476-1","relation":{},"ISSN":["2523-3106"],"issn-type":[{"value":"2523-3106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,24]]},"assertion":[{"value":"17 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board (IRB) of Severance Hospital (IRB No: 4-2024-0628) and was conducted in accordance with the Declaration of Helsinki. The requirement for informed consent was waived owing to the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}